For patients with type 1 diabetes (T1D), managing blood sugar is already a constant, demanding task. What happens to that management when a patient also develops depression or anxiety? Surprisingly, real-world evidence on this question has been limited, largely because the data needed to answer it doesn’t live in any one place.
We set out to close that gap in a new study, to be presented at the International Society for Pharmacoepidemiology (ISPE) Annual Conference, using NorstellaLinQ real-world data and Panalgo’s Instant Health Data (IHD) platform to evaluate the association between depression and anxiety diagnoses and diabetes-related outcomes among individuals with T1D.
Why Claims Data Alone Couldn’t Answer This Question
Claims data can reliably identify a population with type 1 diabetes. What it can’t do is tell you how well that diabetes is being managed. Glycemic control, measured through HbA1c values, is the clearest marker of T1D severity, and it simply isn’t captured in claims. Answering this question properly required lab data and a longitudinal view of each patient’s clinical record, which meant an electronic health record (EHR)-based approach was the only viable path.
Designing a Matched Cohort Study
Using NorstellaLinQ data within IHD, we identified patients with T1D who had an HbA1c measurement near their index date, establishing a clinical baseline for each. Patients who went on to develop depression or anxiety after that point became the case group; patients who didn’t were matched as controls. From there, we tracked changes in HbA1c values, along with acute and chronic complications, including severe hypoglycemia and ketoacidosis, following each patient’s index date.
The findings were notable: Depression and anxiety in patients with T1D were associated with worse glycemic control and an increased risk of complications and mortality. In practical terms, when a patient with type 1 diabetes develops depression or anxiety, their ability to manage their diabetes tends to decline, and they become a more clinically complex patient as a result.
We didn’t look at whether treating the depression itself improves diabetes outcomes; that’s the natural next step. If future research finds that addressing depression and anxiety also improves glycemic control, it would support a stronger causal claim about the relationship between mental health treatment and chronic disease management, rather than simply an association between the two. For now, the association on its own is a meaningful signal for care teams managing complex, comorbid patients.
When a patient with type 1 diabetes develops depression or anxiety, their ability to manage their diabetes tends to decline, and they become a more clinically complex patient as a result.
Why Connected Real-World Data Made the Difference
This study depended on combining structured EHR data, lab values, and diagnosis codes within a single longitudinal view of each patient, something neither claims data nor a single fragmented data source could provide. Glycemic control lives in lab values; complications and mental health diagnoses live in clinical codes. Bringing all of it together in NorstellaLinQ was what made it possible to track the full relationship between mental health and diabetes management over time.
Using IHD also meant the analysis itself moved fast. Designing the study took time, but once the cohort and methodology were defined, running the analysis took about a week, fast enough that this study and a related analysis on antidepressant withdrawal were both submitted to, and accepted at, ISPE in the same cycle. That speed mattered: It allowed for rapid iteration on cohort definitions and matching criteria before locking in a final design.
These findings add to a growing body of evidence that mental health and chronic disease management can’t be treated as separate concerns, particularly for patients managing a demanding condition like type 1 diabetes.
A Signal Worth Acting On
These findings add to a growing body of evidence that mental health and chronic disease management can’t be treated as separate concerns, particularly for patients managing a demanding condition like type 1 diabetes. Identifying which patients are at elevated risk for worse glycemic control and complications is the first step toward more proactive, integrated care.
As this research continues, including future work examining whether depression treatment itself modifies these outcomes, the goal is to give care teams better tools for identifying and supporting their most complex patients before complications occur.
Contact us to find out how NorstellaLinQ and IHD can help you uncover data to improve patient outcomes.
